Publications by authors named "Daniel Wermeling"

Claim this Profile
D
Design and delivery of a new clinical reasoning course.
Valerie Nolt, Jeff Cain, Daniel Wermeling

Curr Pharm Teach Learn· August 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Review of naloxone safety for opioid overdose: practical considerations for new technology and expanded public access.
Daniel P Wermeling

Ther Adv Drug Saf· February 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Intranasal naloxone administration for treatment of opioid overdose.
Amanda Robinson, Daniel P Wermeling

Am J Health Syst Pharm· December 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Naloxone for opioid overdose prevention: pharmacists' role in community-based practice settings.
Abby M Bailey, Daniel P Wermeling

Ann Pharmacother· May 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Survey of naloxone legal status in opioid overdose prevention and treatment.
Leanne Hewlett, Daniel P Wermeling

J Opioid Manag· February 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A response to the opioid overdose epidemic: naloxone nasal spray.
Daniel P Wermeling

Drug Deliv Transl Res· February 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bioavailability and pharmacokinetics of intranasal hydromorphone in patients experiencing vasomotor rhinitis.
George A Davis, Anita C Rudy, Sanford M Archer, Daniel P Wermeling, Patrick J McNamara

Clin Drug Investig· October 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of the behavioral and cardiovascular effects of intranasal and oral d-amphetamine in healthy human subjects.
Joshua A Lile, Shanna Babalonis, Cleeve Emurian, Catherine A Martin, Daniel P Wermeling

J Clin Pharmacol· June 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Opioid harm reduction strategies: focus on expanded access to intranasal naloxone.
Daniel P Wermeling

Pharmacotherapy· July 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A multicenter, open-label, exploratory dose-ranging trial of intranasal hydromorphone for managing acute pain from traumatic injury.
Daniel P Wermeling, Thomas Clinch, Anita C Rudy, David Dreitlein, Selim Suner

J Pain· January 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Intranasal delivery of antiepileptic medications for treatment of seizures.
Daniel P Wermeling

Neurotherapeutics· April 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A pharmacokinetic and pharmacodynamic study, in healthy volunteers, of a rapidly absorbed intranasal midazolam formulation.
Daniel P Wermeling, Kenneth A Record, Sanford M Archer, Anita C Rudy

Epilepsy Res· February 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Research in women and special populations.

Pharmacotherapy· September 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of intranasal administration of haloperidol with intravenous and intramuscular administration: a pilot pharmacokinetic study.
Jodi L Miller, J Wesson Ashford, Sanford M Archer, Anita C Rudy, Daniel P Wermeling

Pharmacotherapy· July 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Microneedles permit transdermal delivery of a skin-impermeant medication to humans.
Daniel P Wermeling, Stan L Banks, David A Hudson, Harvinder S Gill, Jyoti Gupta

Proc Natl Acad Sci U S A· February 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Intranasal absorption of Delta(9)-tetrahydrocannabinol and WIN55,212-2 mesylate in rats.
Satyanarayana Valiveti, Remigius U Agu, Dana C Hammell, Kalpana S Paudel, D Caroline Earles, Daniel P Wermeling

Eur J Pharm Biopharm· February 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics and pharmacodynamics of a new intranasal midazolam formulation in healthy volunteers.
Daniel P Wermeling, Kenneth A Record, Thomas H Kelly, Sanford M Archer, Thomas Clinch

Anesth Analg· August 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Z
Ziconotide infusion for severe chronic pain: case series of patients with neuropathic pain.
Daniel P Wermeling, Joseph R Berger

Pharmacotherapy· March 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics, bioequivalence, and spray weight reproducibility of intranasal butorphanol after administration with 2 different nasal spray pumps.
Daniel P Wermeling, Jodi L Miller, Sanford M Archer, Mary K Rayens, Anita C Rudy

J Clin Pharmacol· August 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Z
Ziconotide, an intrathecally administered N-type calcium channel antagonist for the treatment of chronic pain.
Daniel P Wermeling

Pharmacotherapy· August 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Analgesic effects of intranasal butorphanol tartrate administered via a unit-dose device in the dental impaction pain model: a randomized, double-blind, placebo-controlled, parallel-group study.
Daniel P Wermeling, George M Grant, Allen Lee, Nicole Alexander, Anita C Rudy

Clin Ther· April 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bioavailability of intranasal butorphanol administered from a single-dose sprayer.
George A Davis, Ani Ia C Rudy, Sanford M Archer, Daniel P Wermeling

Am J Health Syst Pharm· January 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A multiple-dose phase I study of intranasal hydromorphone hydrochloride in healthy volunteers.
Anita C Rudy, Barbara A Coda, Sanford M Archer, Daniel P Wermeling

Anesth Analg· November 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Intranasal delivery of recombinant human parathyroid hormone [hPTH (1-34)], teriparatide in rats.
Remigius U Agu, Satyanarayana Valiveti, D Caroline Earles, Mitchell Klausner, Patrick J Hayden, Daniel P Wermeling

Endocr Res· August 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics of butorphanol tartrate administered from single-dose intranasal sprayer.
George A Davis, Anita C Rudy, Sanford M Archer, Daniel P Wermeling

Am J Health Syst Pharm· February 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis